On Nov. 10, 2022, Pfizer and BioNTech announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATYﾮ Original/Omicron BA.4/BA.5 5/5-ﾵg) had been recommended for marketing authorization by the European Medicines Agency Committee for Medicinal Products for Human Use for children 5 through 11 years of age.